Abivax Shares Interim Results On Efficacy And Safety Of Daily 25mg Obefazimod In Moderate To Severe Ulcerative Colitis Patients Following 2 Years Of Open-Label Maintenance
Portfolio Pulse from Benzinga Newsdesk
Abivax has reported positive interim results for its drug Obefazimod, showing efficacy and safety in treating moderate to severe ulcerative colitis over a two-year period. The drug maintained clinical remission and was well-tolerated with no new safety concerns.
October 03, 2024 | 7:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abivax's interim results for Obefazimod show positive efficacy and safety in ulcerative colitis treatment, maintaining clinical remission over two years.
The positive interim results for Obefazimod in maintaining clinical remission in ulcerative colitis patients are likely to boost investor confidence in Abivax. The drug's safety profile and efficacy over a long period are significant for its market potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100